Matching-Adjusted Indirect Comparisons of Efficacy Outcomes in Patients with Relapsed and Refractory Multiple Myeloma for Idecabtagene Vicleucel (KarMMa) Versus Selinexor Plus Dexamethasone (STORM Part 2) and Belantamab Mafodontin (DREAMM-2): Updated Analysis with Longer Follow-up
2021; Elsevier BV; Volume: 138; Issue: Supplement 1 Linguagem: Inglês
10.1182/blood-2021-145321
ISSN1528-0020
AutoresPaula Rodríguez‐Otero, Ali Mojebi, Dieter Ayers, Devender Dhanda, James J. Farrell, Faith E. Davies, Michel Delforge, Katja Weisel, Kevin M. Towle, Tom Marshall, Clyde Caisip, Shannon Cope,
Tópico(s)CAR-T cell therapy research
Referência(s)